531210 Stock Overview
Manufactures, markets, and trades in pharmaceutical formulations in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Colinz Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹52.52 |
| 52 Week High | ₹84.40 |
| 52 Week Low | ₹36.00 |
| Beta | 0.37 |
| 11 Month Change | -3.46% |
| 3 Month Change | 1.29% |
| 1 Year Change | 28.10% |
| 33 Year Change | 173.54% |
| 5 Year Change | 443.69% |
| Change since IPO | 514.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531210 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -12.9% | -0.2% | 0.3% |
| 1Y | 28.1% | 40.5% | 27.3% |
Return vs Industry: 531210 underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: 531210 matched the Indian Market which returned 27.3% over the past year.
Price Volatility
| 531210 volatility | |
|---|---|
| 531210 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 531210's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 531210's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 69 | Narayanan Menon | www.colinz.com |
Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, and creams, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, and pegylated liposome doxorubicin, etc.; antiritrovirals, including lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormones, sunscreens, and vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. In addition, the company offers ayurvedic products comprising anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction.
Colinz Laboratories Limited Fundamentals Summary
| 531210 fundamental statistics | |
|---|---|
| Market cap | ₹132.30m |
| Earnings (TTM) | ₹5.03m |
| Revenue (TTM) | ₹68.77m |
26.3x
P/E Ratio1.9x
P/S RatioIs 531210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531210 income statement (TTM) | |
|---|---|
| Revenue | ₹68.77m |
| Cost of Revenue | ₹22.72m |
| Gross Profit | ₹46.04m |
| Other Expenses | ₹41.02m |
| Earnings | ₹5.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.00 |
| Gross Margin | 66.96% |
| Net Profit Margin | 7.31% |
| Debt/Equity Ratio | 6.4% |
How did 531210 perform over the long term?
See historical performance and comparison